U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H9O5.Na
Molecular Weight 280.208
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SALSALATE SODIUM

SMILES

[Na+].OC1=CC=CC=C1C(=O)OC2=CC=CC=C2C([O-])=O

InChI

InChIKey=JOCPDKGMOXSKRO-UHFFFAOYSA-M
InChI=1S/C14H10O5.Na/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17;/h1-8,15H,(H,16,17);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H9O5
Molecular Weight 257.2183
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23817699 | https://www.ncbi.nlm.nih.gov/pubmed/6520777

Salsalate is a dimer of salicylic acid. Upon administration, it is metabolically hydrolyzed to salicylic acid. Salsalate is is a nonsteroidal anti-inflammatory agent for oral administration for treatment of rheumatoid arthritis, osteoarthritis and related rheumatoid disorders. In addition, salsalate is investigated for treatment of type 2 diabetes.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: GO:0001516
Sources: Salsalate selectively inhibits prostaglandin synthesis in vivo
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DISALCID

Approved Use

Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, and related rheumatic disorder.
Palliative
DISALCID

Approved Use

Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Salicylic acid-induced inactivation of creatine kinase in the presence of lactoperoxidase and H2O2.
2005 Jan 15
Phenolic compounds, sodium salicylate and related compounds, as inhibitors of tumor cell growth and inducers of apoptosis in mouse leukemia L1210 cells.
2005 Jan-Feb
siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle.
2008 Aug
Salsalate improves glycemia and inflammatory parameters in obese young adults.
2008 Feb
A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women.
2009 Jan
Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury.
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Apocynin improves insulin resistance through suppressing inflammation in high-fat diet-induced obese mice.
2010
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Potential role of salicylates in type 2 diabetes.
2010 Jul-Aug
Patents

Sample Use Guides

In Vivo Use Guide
The usual dosage is 3000 mg daily, given in divided doses as follows: 1(two doses of two 750 mg tablets; 2) two doses of three 500 mg tablets; or 3) three doses of two 500 mg tablets.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:11:44 GMT 2023
Edited
by admin
on Sat Dec 16 11:11:44 GMT 2023
Record UNII
06SH0H2G8M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SALSALATE SODIUM
Common Name English
SODIUM SALICYLSALICYLATE
Systematic Name English
2-HYDROXYBENZOIC ACID 2-CARBOXYPHENYL ESTER SODIUM SALT
Systematic Name English
BENZOIC ACID, 2-HYDROXY-, 2-CARBOXYPHENYL ESTER, MONOSODIUM SALT
Systematic Name English
Code System Code Type Description
FDA UNII
06SH0H2G8M
Created by admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
PRIMARY
PUBCHEM
23662396
Created by admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
PRIMARY
EPA CompTox
DTXSID40178111
Created by admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
PRIMARY
CAS
23520-54-9
Created by admin on Sat Dec 16 11:11:45 GMT 2023 , Edited by admin on Sat Dec 16 11:11:45 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY